Found: The Lord O'Shaughnessy review into commercial clinical trials in the UK ( 8) was commissioned by the

Found: The Lord O'Shaughnessy review into commercial clinical trials in the UK ( 8) was commissioned by the

Found: Lord O'Shaughnessy Oral Evidence

Found: Lord O'Shaughnessy: You will be pleased to know that we are having a round table with the Royal Academy

Found: Lord O'Shaughnessy: Yes, indeed, in preparation rather than in response.Leigh Pomlett: Yes, please, or

Found: Lord O'Shaughnessy: It would be good to get your thoughts on whether there are other risks that we are

Found: Lord O'Shaughnessy: Thank you.

Found: Lord O'Shaughnessy: If it is not your secretariat™s responsibility, ought there to be someone somewhere

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make it his policy to implement the recommendations of Blood Cancer UK's Action Plan.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancer, as quickly as possible to treat it faster and to improve outcomes. This is supported by NHS England’s key ambition on cancer to meet the Faster Diagnosis Standard, which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out.

The Department is committed to implementing the recommendations of the Lord O'Shaughnessy review into commercial clinical trials making sure that the United Kingdom leads the world in clinical trials, and to ensure that innovative, lifesaving treatments are accessible to NHS patients, including those with blood cancer.

Professor Lord Darzi has undertaken an independent investigation into the state of the NHS, the findings of which will feed into the Government’s 10-year plan to build a health service that is fit for the future. The Government will therefore set out any further priorities on cancer and health in due course.

I would be happy to meet the Hon. member to discuss the Blood Cancer UK Action Plan.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential implications for his Department's policies of the recommendations of Blood Cancer UK's Action Plan.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Department has not made a formal assessment of the potential implications of its policies based on the recommendations of Blood Cancer UK’s Action Plan.

However, we will get the National Health Service diagnosing cancer earlier and treating it faster. This is supported by NHS England’s key ambition on cancer to meet the Faster Diagnosis Standard, which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out.

The Department is committed to implementing the recommendations of the Lord O'Shaughnessy review into commercial clinical trials, making sure that the United Kingdom leads the world in clinical trials, and to ensure that innovative, lifesaving treatments are accessible to NHS patients, including those with blood cancer.

Professor Lord Darzi has undertaken an independent investigation into the state of the NHS, the findings of which will feed into the Government’s 10-year plan to build a health service that is fit for the future. The Government will therefore set out any further priorities on cancer and health in due course.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled Full government response to the Lord O'Shaughnessy review into commercial clinical trials, last updated on 8 December 2023, what her Department's planned timetable is for expanding the national contract value review programme to phase 1 and 2a clinical trials.

Answered by Andrew Stephenson

The National Contract Value Review (NCVR) process applies to commercial clinical studies. NHS England is working in partnership with the devolved administrations, the National Institute for Health and Care Research, and other partners, to pilot the use of the NCVR process for phase I and IIa of commercial clinical trials. The ambition is to make the use of NCVR for phase I and IIa of commercial clinical trials mainstream from October 2024.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department has taken to implement the (a) significant actions under problem statement 6 and (b) other recommendations of the Lord O'Shaughnessy review of commercial clinical trials.

Answered by Andrew Stephenson

The Government will soon publish a full response to the Lord O’Shaughnessy independent review into commercial clinical trials.

The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023 as well as all other recommendations in the review.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 6 April 2017 (HL6515), whether the Human Fertilisation and Embryology Authority has been made aware that any child born as a result of mitochondrial donation has (1) a mitochondrial disease, (2) birth defect, (3) genetic abnormality, or (4) any other adverse outcome.

Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)

The Human Fertilisation and Embryology Authority has advised that it cannot provide the detailed information as requested as it may compromise patient confidentiality.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, with reference to the press release entitled Lord O'Shaughnessy to lead independent review into UK clinical trials, published on 20 February 2023, how many staff from the Department of (a) Science, Innovation and Technology, (b) Health and Social Care and (c) Business and Trade will be involved in the review.

Answered by George Freeman

The Office for Life Sciences is providing secretariat support for the review and is a joint unit between Department for Health and Social Care and Department for Science, Innovation and Technology. Three members of OLS staff are involved in this secretariat function as part of their roles. No members of the Department for Business and Trade are providing direct support. Officials from both DHSC and DSIT are providing evidence for the review as experts in Clinical Research.

Question to the Department for Science, Innovation & Technology:

To ask Secretary of State for Science, Innovation and Technology, with reference to the press release entitled Lord O'Shaughnessy to lead independent review into UK clinical trials, published on 20 February 2023, what the salary for leading the review is.

Answered by George Freeman

Lord O’Shaughnessy has been appointed as Chair for the independent review into UK clinical trials. Lord O’Shaughnessy is not a government official and the role is unpaid.

Question to the Department for Science, Innovation & Technology:

To ask Secretary of State for Science, Innovation and Technology, with reference to the press release entitled Lord O'Shaughnessy to lead independent review into UK clinical trials, published on 20 February 2023, what budget her Department has allocated to the review.

Answered by George Freeman

No specific budget has been allocated to the review. Existing staff have been temporarily re-allocated in order to support the running of the review.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what records his Department holds of correspondence between Lord O'Shaughnessy and companies providing covid-19 testing or testing supplies, between April and August 2020, conducted on his private gmail account; and whether he was provided with a departmental email address in his capacity as an adviser on NHS Test and Trace during this period.

Answered by Edward Argar - Shadow Secretary of State for Health and Social Care

The Department holds copies of correspondence between Lord O’Shaughnessy’s Gmail account and Government officials, companies and organisations working on COVID-19 testing and testing supplies issues between April and August 2020. During this period Lord O’Shaughnessy was provided with a Departmental email address.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department holds a minute of the meetings between the Parliamentary Under Secretary of State for Innovation, Lord O'Shaughnessy and OC&C strategy consultants on 13 April 2020; who attended the meeting on behalf of OC&C; whether officials or special advisers attended the meeting on behalf of his Department; and in what capacity Lord O'Shaughnessy was attending.

Answered by Edward Argar - Shadow Secretary of State for Health and Social Care

The Department holds notes of the actions arising from this meeting. Lord Bethell was supported by a private secretary, Departmental officials and officials from the Department for International Trade, Department for Environment, Food and Rural Affairs and NHS England. Lord O'Shaughnessy and Bennet Summers, Vivek Madan and Henry Stannard of OC&C Strategy also attended the meeting. Special advisors were not present. Lord O'Shaughnessy attended in an advisory capacity.

Found: Answering member: Lord O'Shaughnessy | Department: Department of Health and Social Care The Government

Found: The Lord O'Shaughnessy review into commercial clinical trials in the UK ( 8) was commissioned by the

Found: Government response to the review into commercial clinical trials The full government response to the Lord

Found: Full government response to the Lord O'Shaughnessy review into commercial clinical trials. 40p.

Found: Asked for her views on the recently published Lord O'Shaughnessy report which makes a series of re